Clinical trials: Urinary
Urothelial Carcinoma, Bladder Cancer
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
The purpose of this trial is to determine the benefit of the combination of nab-paclitaxel plus gemcitabine given for 6 cycles, followed by maintenance nab-paclitaxel alone, in patients with cisplatin-ineligible or…
- Conditions
- Urothelial Carcinoma, Bladder Cancer, Transitional Cell Carcinoma
- Trial name
- NCT02887248
- Testing
- nab-paclitaxel, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- SCRI Development Innovations, LLC
Urinary Bladder, Neurogenic
Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients
The proposed study is a randomized, double blind placebo controlled multicenter study to determine the effectiveness of mirabegron in the treatment of neurogenic bladder dysfunction.
- Trial name
- NCT02044510
- Testing
- Mirabegron
- Where
- 5 sites in Canada
- Volunteers
- 32 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Overactive Bladder
Over Active Bladder Patients Having Sling Surgery
The purpose of this study is to determine whether treatment with anti-muscarinic medications following sub-urethral sling procedures improves overall subjective and objective outcomes in women with mixed incontinence with primary…
- Trial name
- NCT00852696
- Testing
- Solifenacin
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Cleveland Clinic Florida
Urinary Tract Infection
Preventing Urinary Tract Infection Post-Surgery
Approximately 10-27% of patients undergoing gynecologic surgeries develop a catheter associated urinary tract infection (CAUTI) in the post operatory period, as bladder catheterization is a common practice in gynecologic surgery.
- Trial name
- PUPS (NCT01346774)
- Testing
- Cranberry powder capsules
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Betsy Foxman
Recurrent Bladder Carcinoma, Stage I Bladder Cancer AJCC v6 and v7
Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer
Studying samples of blood, urine, and tissue from patients with cancer in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Conditions
- Recurrent Bladder Carcinoma, Stage I Bladder Cancer AJCC v6 and v7, Stage II Bladder Cancer AJCC v6 and v7, Stage III Bladder Cancer AJCC v6 and v7
- Trial name
- NCT00118040
- Testing
- Genistein, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Nocturia
Study Investigating the Impact Burden of Nocturia Using the Nocturia Impact Diary
The purpose of this study is to assess psychometric properties (reliability and validity) of the Nocturia Impact (NI) diary. To assess the association between reduction of number of nocturnal voids and the mean changes in NI…
- Trial name
- IMPACT (NCT01552343)
- Testing
- Desmopressin
- Where
- 10 sites in United States
- Volunteers
- 56 people
- Sponsor
- Ferring Pharmaceuticals
Overactive Bladder, Overactive Urinary Bladder
A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)
The study is designed to investigate the effects of the investigational drug vibegron (MK-4618) compared to placebo on maximum urinary bladder capacity in women with overactive bladder.
- Trial name
- NCT01500382
- Testing
- Vibegron, Tolterodine ER, Prophylactic Antibiotic
- Volunteers
- 4 people
- Sponsor
- Merck Sharp & Dohme LLC
Intermittent Urethral Catheterization
Safety and Performance of a New Coating for Urinary Intermittent Catheters
The aim of the study is to evaluate safety and performance of a new catheter coating,compared to the current SpeediCath coating.
- Trial name
- NCT01800903
- Testing
- ZN-D catheter, ZN-C catheter, SpeediCath catheter
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Coloplast A/S
Overactive Bladder, Overactive Bladder Syndrome
OnabotulinumtoxinA Bladder Injection Study
Patients with overactive bladder (OAB) will be randomly assigned (like a flip of a coin) to receive 100 units of onabotulinumtoxinA injected into the bladder at either 3 sites or 10 sites.
- Conditions
- Overactive Bladder, Overactive Bladder Syndrome, Urinary Urgency, Urinary Incontinence
- Trial name
- NCT03523091
- Testing
- OnabotulinumtoxinA 100Unit Injection
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Corewell Health East
Overactive Bladder, Urinary Incontinence
The Effect of Urox™ in the Treatment of Overactive Bladder and Urinary Incontinence
This study aims to assess the efficacy of a specialized herbal formula, Urox, versus control over 8 weeks, in a double blind, placebo controlled trial.
- Conditions
- Overactive Bladder, Urinary Incontinence, Urinary Frequency or Urgency Adverse Event, Nocturia
- Trial name
- NCT02396160
- Testing
- Urox
- Volunteers
- 150 people
- Sponsor
- The University of Queensland
Urinary Tract Infections
A Study in Adolescent and Adult Female Participants to Evaluate Clinical Symptom Improvement and the Safety of Gepotidacin During Treatment of Uncomplicated Urinary Tract Infections (Acute Cystitis)
The study will be conducted to evaluate the clinical symptom improvement and safety of oral gepotidacin for treatment of uncomplicated UTI (acute cystitis) in adolescent and adult female participants.
- Trial name
- SIS (NCT06597344)
- Testing
- Gepotidacin
- Where
- 22 sites in United States
- Volunteers
- 97 people
- Sponsor
- GlaxoSmithKline
Nocturia Associated With Nocturnal Polyuria
Efficacy and Safety of Desmopressin (Nocturin®) 0.1 mg Tablets in Treatment of Nocturia in Participants With Benign Prostate Syndrome (BPS)
Documentation of the efficacy and safety of desmopressin (Nocturin®) 0.1 mg tablet. Observation of patients with benign prostate syndrome, in whom nocturia associated with nocturnal polyuria is treated with desmopressin…
- Trial name
- NCT00902265
- Testing
- desmopressin
- Where
- 140 sites in Germany
- Volunteers
- 138 people
- Sponsor
- Ferring Pharmaceuticals
Hyperlipidemia
Biosynthesis of PGD2 in Vivo
The investigator would like to see if aspirin could block niacin-induced flushing by analyzing blood and urine after taking aspirin. Phase I: Subjects were assigned to either placebo or aspirin groups.
- Trial name
- NCT01275300
- Testing
- Aspirin, Niacin
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Ureteral Cancer, Urothelial Cancer
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
The purpose of this study was to compare the overall survival (OS) of participants with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin (EV) to the OS of participants treated with chemotherapy.
- Conditions
- Ureteral Cancer, Urothelial Cancer, Bladder Cancer
- Trial name
- NCT03474107
- Testing
- Enfortumab Vedotin, Docetaxel, Vinflunine
- Where
- 158 sites in United States, Argentina and 17 more
- Volunteers
- 608 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Urinary Incontinence, Sarcopenia
The Urinary Incontinence Treatment Study
Investigators plan a prospective cohort study with an adaptive design based on physical function status. The design will involve tracking the number of women recruited with physical function impairment and those without any…
- Trial name
- UNITS (NCT03057834)
- Testing
- Pelvic floor muscle exercise
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Nocturia
Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia
The purpose of this study is to determine if SER120 nasal spray is well tolerated in 75 years or older nocturic patients.
- Trial name
- NCT01259128
- Testing
- SER120 Nasal Spray 500 ng/day, SER120 nasal spray 750 ng/day
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Serenity Pharmaceuticals, Inc.
Lower Urinary Tract Symptoms, Overactive Bladder
Tetra-NIRS Clinical Study
The purpose of this evaluation is to validate the previous clinical study results using a Near-Infrared Spectroscopy (NIRS) device, as compared to the conventional urodynamics (UDS) testing.
- Trial name
- NCT00871975
- Testing
- Urodynamics + TETRA - NIRS
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 155 people
- Sponsor
- Laborie Medical Technologies Inc.
Urinary Tract Infection, Recurrent Urinary Tract Infection
Effects of Antibiotic Prophylaxis on Recurrent UTI in Children
Approximately, 3% of males and 8% of females will develop a urinary tract infection (UTI) during childhood, and most of these will be effectively treated by short-term antibiotic therapy.
- Trial name
- NCT02357758
- Testing
- Antibiotic Prophylaxis
- Where
- Canada
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Recurrent Bladder Cancer, Stage III Bladder Cancer
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
This phase II trial studies how well giving docetaxel and lapatinib ditosylate together as second-line therapy works in treating patients with stage IV bladder cancer that cannot be removed by surgery.
- Conditions
- Recurrent Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder
- Trial name
- NCT01382706
- Testing
- docetaxel, lapatinib ditosylate, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Southern California
Bladder Cancer, Cancer of the Bladder, Recurrent
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
Bladder cancer is the most common urinary tract cancer and the 5th most common cancer in the US (1). Yet bladder cancer research is underfunded relative to other common cancers.
- Conditions
- Bladder Cancer, Cancer of the Bladder, Recurrent, Non-muscle Invasive Bladder Cancer
- Trial name
- CISTO (NCT03933826)
- Where
- 36 sites in United States
- Volunteers
- 570 people
- Sponsor
- University of Washington
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.